Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,527,586
  • Shares Outstanding, K 41,730
  • Annual Sales, $ 130 K
  • Annual Income, $ -245,870 K
  • 36-Month Beta 1.92
  • Price/Sales 19,464.23
  • Price/Cash Flow 0.00
  • Price/Book 5.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.17 +9.15%
on 04/11/17
71.41 -14.14%
on 03/27/17
-9.01 (-12.81%)
since 03/24/17
3-Month
56.17 +9.15%
on 04/11/17
91.35 -32.88%
on 03/02/17
-8.73 (-12.46%)
since 01/24/17
52-Week
46.52 +31.79%
on 06/27/16
91.35 -32.88%
on 03/02/17
-14.71 (-19.35%)
since 04/22/16

Most Recent Stories

More News
What's in Store for Vertex (VRTX) this Earnings Season?

Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.

RARE : 61.31 (+1.22%)
PTI : 5.48 (-4.53%)
LLY : 83.42 (+1.87%)
VRTX : 117.66 (+0.82%)
What's in Store for AbbVie (ABBV) this Earnings Season?

AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.

RARE : 61.31 (+1.22%)
PTI : 5.48 (-4.53%)
JNJ : 122.89 (+0.93%)
ABBV : 64.66 (+1.32%)
Ultragenyx Pharmaceutical Enters Oversold Territory (RARE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

RARE : 61.31 (+1.22%)
Company News for April 20, 2017

Companies in the News are: LRCX,FB,RARE,ABT

ABT : 44.13 (+1.38%)
RARE : 61.31 (+1.22%)
LRCX : 142.51 (+1.81%)
FB : 145.47 (+1.25%)
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with...

HSKA : 107.40 (+2.12%)
GALE : 0.58 (unch)
RARE : 61.31 (+1.22%)
INFI : 1.96 (+2.08%)
Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-linked Hypophosphatemia

NOVATO, California, LONDON and TOKYO, April 18, 2017 /PRNewswire/ --

RARE : 61.31 (+1.22%)
Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia

Study met primary endpoint of serum phosphorus response and key secondary endpoint of stiffness improvement

RARE : 61.31 (+1.22%)
Ultragenyx's (RARE) XLH Drug Positive in Phase II Study

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin International plc recently announced positive 64-week data from a pediatric phase II study, evaluating its investigational candidate...

HSKA : 107.40 (+2.12%)
GALE : 0.58 (unch)
RARE : 61.31 (+1.22%)
INFI : 1.96 (+2.08%)
Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of Deborah Dunsire,...

RARE : 61.31 (+1.22%)
Ultragenyx and Kyowa Kirin International Announce Positive Data from Pediatric Phase 2 Studies of Burosumab (KRN23) in X-Linked Hypophosphatemia

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Kirin International PLC (KKI), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), today announced positive 64-week data...

RARE : 61.31 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Support & Resistance

2nd Resistance Point 62.63
1st Resistance Point 61.97
Last Price 61.31
1st Support Level 60.84
2nd Support Level 60.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.